• Je něco špatně v tomto záznamu ?

Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial

P. Kelly, C. Weimar, R. Lemmens, S. Murphy, F. Purroy, A. Arsovska, NM. Bornstein, A. Czlonkowska, U. Fischer, AC. Fonseca, J. Forbes, MD. Hill, D. Jatuzis, J. Kõrv, C. Kruuse, R. Mikulik, P. J Nederkoorn, M. O'Donnell, P. Sandercock, D. Tanne,...

. 2021 ; 6 (2) : 222-228. [pub] 20210618

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024625

Background: Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events.Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone. Design: CONVINCE is a multi-centre international (in 17 countries) Prospective, Randomised Open-label, Blinded-Endpoint assessment (PROBE) controlled Phase 3 clinical trial in 3154 participants. The intervention is colchicine 0.5 mg/day and usual care versus usual care alone (antiplatelet, lipid-lowering, antihypertensive treatment, lifestyle advice). Included patients are at least 40 years, with non-severe ischaemic stroke (modified Rankin score ≤3) or high-risk TIA (ABCD2 > 3, or positive DWI, or cranio-cervical artery stenosis) within 72 hours-28 days of randomisation, with qualifying stroke/TIA most likely caused by large artery stenosis, lacunar disease, or cryptogenic embolism. Exclusions are stroke/TIA caused by cardio-embolism or other defined cause (e.g. dissection), contra-indication to colchicine (including potential drug interactions), or incapacity for participation in a clinical trial. The anticipated median follow-up will be 36 months. The primary analysis will be by intention-to-treat. Outcome: The primary outcome is time to first recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation with unstable angina (non-fatal or fatal). Summary: CONVINCE will provide high-quality randomised data on the efficacy and safety of anti-inflammatory therapy with colchicine for secondary prevention after stroke. Schedule: First-patient first-visit was December 2016. Recruitment to complete in 2021, follow-up to complete in 2023.

2nd Department of Neurology Attikon Hospital National and Kapodistrian University of Athens School of Medicine Athens Greece

2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland

Amsterdam University Medical Centers Department of Neurology | Location AMC Amsterdam The Netherlands

Centre for Clinical Brain Sciences Edinburgh UK

Centre for Clinical Brain Sciences University of Edinburgh UK

Centre of Neurology Institute of Clinical Medicine Faculty of Medicine Vilnius University Lithuania

Department of Neurology and Neurosurgery University of Tartu Tartu Estonia

Department of Neurology University Hospital Bern Inselspital University of Bern Bern Switzerland

Health Research Board Stroke Clinical Trials Network Ireland

Herlev Gentofte Hospital and University of Copenhagen Denmark

HRB Clinical Research Facility Galway and National University of Ireland Galway Ireland

Institut für Medizinische Informatik Biometrie und Epidemiologie Universitätsklinikum Essen University Duisburg Essen Essen Germany

Institute of Neuroscience Newcastle University Newcastle UK

International Clinical Research Center and Neurology Department St Anne's University Hospital and Masaryk University Brno Czech Republic

Mater University Hospital and University College Dublin Ireland

Mathematics Applications Consortium for Science and Industry and Health Research Institute University of Limerick Ireland

Neurology Unit Stroke Unit Azienda Unità Sanitaria locale IRCCS di Reggio Emilia Italy

RCSI University of Medicine and Health Sciences and Beaumont Hospital Dublin Ireland

School of Medicine University of Limerick Limerick Ireland

Shaare Zedek Medical Center Jerusalem Israel

Stroke Centre and Clinical Trial Unit University of Bern Bern Switzerland

Stroke Unit Department of Neurology Hospitalt Universitari Arnau de Vilanova de Lleida Spain

Universitat de Lleida Biomedical Research Institute of Lleida Spain

University Clinic of Neurology Medical Faculty University Ss Cyril and Methodius Skopje North Macedonia

University Hospitals Leuven Department of Neurology Leuven Belgium

University of Calgary and Foothills Medical Centre Calgary Alberta Canada

VIB Center for Brain and Disease Research Laboratory of Neurobiology Leuven Belgium

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024625
003      
CZ-PrNML
005      
20211013133833.0
007      
ta
008      
211006s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/2396987320972566 $2 doi
035    __
$a (PubMed)34414298
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kelly, Peter $u Mater University Hospital and University College Dublin, Ireland $u Health Research Board Stroke Clinical Trials Network, Ireland
245    10
$a Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial / $c P. Kelly, C. Weimar, R. Lemmens, S. Murphy, F. Purroy, A. Arsovska, NM. Bornstein, A. Czlonkowska, U. Fischer, AC. Fonseca, J. Forbes, MD. Hill, D. Jatuzis, J. Kõrv, C. Kruuse, R. Mikulik, P. J Nederkoorn, M. O'Donnell, P. Sandercock, D. Tanne, G. Tsivgoulis, C. Walsh, D. Williams, M. Zedde, CI. Price
520    9_
$a Background: Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events.Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone. Design: CONVINCE is a multi-centre international (in 17 countries) Prospective, Randomised Open-label, Blinded-Endpoint assessment (PROBE) controlled Phase 3 clinical trial in 3154 participants. The intervention is colchicine 0.5 mg/day and usual care versus usual care alone (antiplatelet, lipid-lowering, antihypertensive treatment, lifestyle advice). Included patients are at least 40 years, with non-severe ischaemic stroke (modified Rankin score ≤3) or high-risk TIA (ABCD2 > 3, or positive DWI, or cranio-cervical artery stenosis) within 72 hours-28 days of randomisation, with qualifying stroke/TIA most likely caused by large artery stenosis, lacunar disease, or cryptogenic embolism. Exclusions are stroke/TIA caused by cardio-embolism or other defined cause (e.g. dissection), contra-indication to colchicine (including potential drug interactions), or incapacity for participation in a clinical trial. The anticipated median follow-up will be 36 months. The primary analysis will be by intention-to-treat. Outcome: The primary outcome is time to first recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation with unstable angina (non-fatal or fatal). Summary: CONVINCE will provide high-quality randomised data on the efficacy and safety of anti-inflammatory therapy with colchicine for secondary prevention after stroke. Schedule: First-patient first-visit was December 2016. Recruitment to complete in 2021, follow-up to complete in 2023.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Weimar, Christian $u Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universitätsklinikum Essen, University Duisburg-Essen, Essen, Germany
700    1_
$a Lemmens, Robin $u VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium $u VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium $u University Hospitals Leuven, Department of Neurology, Leuven, Belgium
700    1_
$a Murphy, Sean $u Mater University Hospital and University College Dublin, Ireland $u Health Research Board Stroke Clinical Trials Network, Ireland
700    1_
$a Purroy, Francisco $u Stroke Unit, Department of Neurology, Hospitalt Universitari Arnau de Vilanova de Lleida, Spain $u Universitat de Lleida, Biomedical Research Institute of Lleida (IRBLleida) , Universitat de Lleida (UdL), Spain
700    1_
$a Arsovska, Anita $u University Clinic of Neurology, Medical Faculty, University "Ss Cyril and Methodius", Skopje, North Macedonia
700    1_
$a Bornstein, Natan M $u Shaare-Zedek Medical Center, Jerusalem, Israel
700    1_
$a Czlonkowska, Anna $u Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland
700    1_
$a Fischer, Urs $u Stroke Centre and Clinical Trial Unit, University of Bern, Bern, Switzerland
700    1_
$a Fonseca, Ana Catarina $u Department of Neurology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland
700    1_
$a Forbes, John $u School of Medicine, University of Limerick, Limerick, Ireland
700    1_
$a Hill, Michael D $u University of Calgary & Foothills Medical Centre, Calgary, Alberta, Canada
700    1_
$a Jatuzis, Dalius $u Centre of Neurology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania
700    1_
$a Kõrv, Janika $u Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia
700    1_
$a Kruuse, Christina $u Herlev Gentofte Hospital and University of Copenhagen, Denmark
700    1_
$a Mikulik, Robert $u International Clinical Research Center and Neurology Department, St. Anne's University Hospital and Masaryk University Brno, Czech Republic
700    1_
$a J Nederkoorn, Paul $u Amsterdam University Medical Centers (AUMC), Department of Neurology | Location AMC, Amsterdam, The Netherlands
700    1_
$a O'Donnell, Martin $u HRB Clinical Research Facility Galway and National University of Ireland Galway, Ireland
700    1_
$a Sandercock, Peter $u Centre for Clinical Brain Sciences, Edinburgh, UK
700    1_
$a Tanne, David $u Centre for Clinical Brain Sciences, University of Edinburgh UK
700    1_
$a Tsivgoulis, Georgios $u Second Department of Neurology, "Attikon" Hospital, National and Kapodistrian, University of Athens, School of Medicine, Athens, Greece
700    1_
$a Walsh, Cathal $u Mathematics Applications Consortium for Science and Industry and Health Research Institute, University of Limerick, Ireland
700    1_
$a Williams, David $u RCSI University of Medicine and Health Sciences and Beaumont Hospital, Dublin, Ireland $u RCSI University of Medicine and Health Sciences and Beaumont Hospital, Dublin, Ireland
700    1_
$a Zedde, Marialuisa $u Neurology Unit, Stroke Unit, Azienda Unità Sanitaria locale-IRCCS di Reggio Emilia, Italy
700    1_
$a Price, Christopher I $u Institute of Neuroscience, Newcastle University, Newcastle, UK
773    0_
$w MED00200144 $t European stroke journal $x 2396-9881 $g Roč. 6, č. 2 (2021), s. 222-228
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34414298 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133831 $b ABA008
999    __
$a ind $b bmc $g 1708403 $s 1145122
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 6 $c 2 $d 222-228 $e 20210618 $i 2396-9881 $m European stroke journal $n Eur Stroke J $x MED00200144
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Možnosti archivace